PRESS RELEASES

Found 251 Results
Page 3 of 26

“La France bouge” – Europe 1 : Interview of Judith Greciet


(in French only)   Watch the interview  

Tags:

02/04/2020

Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer


The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to […]

Tags:

01/29/2020

Onxeo to Present Next-Generation PARP inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020


Paris (France), January 28, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

01/28/2020

Onxeo Publishes Shareholder Newsletter


Paris (France), January 20, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

01/20/2020

Onxeo Announces its Financial Agenda for 2020


  Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]

Tags:

12/09/2019

Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology


In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]

Tags:

11/13/2019

Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.


Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

11/05/2019

Page 3 of 26
Onxeo Announces its Financial Agenda for 2020
09-12-2019
Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology
13-11-2019
Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.
05-11-2019
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment
04-11-2019
Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000
17-10-2019
Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
15-10-2019
Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform
14-10-2019
Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy
18-09-2019
Onxeo to Attend Key Investor and Scientific Conferences
11-09-2019
Onxeo Reports Half-Year 2019 Financial Results and Provides Business Update
25-07-2019

Last updated on